A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Triple-Negative Breast Cancer
Interventions: DRUG: camrelizumab in combination with nab-paclitaxel and famitinib
Sponsor: Fudan University